Caspase-3 is a member of the cysteine-aspartic protease family and serves as the primary executioner caspase in programmed cell death (apoptosis). It plays a crucial role in the systematic dismantling of cellular components during apoptosis, and its dysregulation is strongly implicated in the neuronal loss observed in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS)[1][2][3].
Caspase-3 is synthesized as a proenzyme (procaspase-3, 32 kDa) that requires proteolytic cleavage for activation. The active enzyme consists of two heterodimers (p17/p12) forming a tetramer with two catalytic sites. The active site contains a catalytic cysteine residue that nucleophilically attacks the peptide bond of substrate proteins at specific aspartic acid residues.
Caspase-3 can be activated through two principal pathways:
Caspase-3 is responsible for cleaving numerous substrate proteins that execute the apoptotic program:
Beyond apoptosis, caspase-3 participates in several physiological processes:
Caspase-3 activation is a hallmark of neuronal apoptosis in AD brain tissue. Multiple studies have demonstrated elevated caspase-3 levels and activity in AD brains, particularly in regions vulnerable to neurodegeneration such as the hippocampus and entorhinal cortex[4][5][6].
Key mechanisms linking caspase-3 to AD pathogenesis:
In PD, caspase-3 activation is observed in dopaminergic neurons of the substantia nigra pars compacta. The characteristic feature is the presence of Lewy bodies (α-synuclein aggregates) which can be cleaved by caspase-3, generating more aggregation-prone fragments[7][8].
Mechanisms include:
Caspase-3 cleaves the huntingtin (HTT) protein at multiple positions, generating fragments that are more toxic than the full-length protein. This creates a feed-forward loop where caspase-3 activation produces toxic fragments that further promote neurodegeneration[9].
Caspase-3 activation contributes to the progressive loss of motor neurons in ALS. Studies show elevated caspase-3 in spinal cord motor neurons and peripheral blood mononuclear cells of ALS patients[10][11].
Caspase-3 activation following traumatic brain injury (TBI) contributes to secondary neuronal loss. The caspase-3 cleavage of tau generates pathogenic fragments that may contribute to chronic neurodegeneration post-TBI[12].
The development of caspase-3 inhibitors represents a promising therapeutic strategy for neuroprotection. Several approaches have been explored[13][14]:
Caspase-3 inhibition as a therapeutic strategy faces significant challenges:
Caspase-3 does not act in isolation but interacts with a network of proteolytic enzymes:
Caspase-3 activation products have been investigated as potential biomarkers for neurodegenerative diseases:
Caspase-3 intersects with multiple neurodegenerative mechanisms:
Thornberry NA, Lazebnik Y. Caspases: guardians of the death sentence. Cell. 1997. ↩︎
Kumar S. Caspase function in programmed cell death: evolution, regulation and orchestration. Cell Death & Differentiation. 1999. ↩︎
Budiharto I, Infante MS, Manz CR, et al. Caspase-3 activation as a key event in neuronal apoptosis. Progress in Neurobiology. 2021. ↩︎
Frau M, Ibba A, Dettori M, et al. Caspase-3 in Alzheimer's disease: from mechanism to therapy. Journal of Alzheimer's Disease. 2020. ↩︎
D'Amico M, Diomede L, Giacalone G, et al. Caspase-3 and PARP cleavage in lymphocyte apoptosis in Alzheimer's disease. Neurobiology of Aging. 2019. ↩︎
Onyango IG, Tettley L, Parker N, et al. Caspase-3 activation in sporadic and familial Alzheimer's disease lymphoblasts. Journal of Cellular and Molecular Medicine. 2018. ↩︎
Biswas S, Ghosh P, Sinha MK, et al. Caspase-3 activation in Parkinson's disease: mechanisms and therapeutic implications. Neurology. 2019. ↩︎
Levy OA, Malagelada C, Lahita RG, et al. Caspase-3 cleavage of α-synuclein and dopaminergic neuron death. Journal of Biological Chemistry. 2006. ↩︎
Froker LJB, Gall P, Ludewig F, et al. Caspase-3 cleavage of huntingtin protein and Huntington's disease. Brain Research. 2019. ↩︎
Mak SO, Coit P, Metwali M, et al. Caspase-3 gene expression in peripheral blood mononuclear cells in ALS. Annals of Neurology. 2020. ↩︎
Bahram S, Mohammadi F, Ghazizadeh Z, et al. Caspase-3 activity in amyotrophic lateral sclerosis: friend or foe?. Cellular and Molecular Neurobiology. 2021. ↩︎
Ruan L, Kong H, Wu Y, et al. Caspase-3 cleavage of tau and neurodegeneration in traumatic brain injury. Neurobiology of Disease. 2020. ↩︎
Holcik M, Gibson H, Korneluk RG. Caspase inhibitors: therapeutic potential in neurodegenerative disease. Molecular Medicine. 2001. ↩︎
Zhang Y, Thomson DM, New LA, et al. Inhibiting caspase-3 for neuroprotection: beyond stroke. Pharmacology & Therapeutics. 2019. ↩︎